US FDA Objects to Dendreon Corporation Promotions for Provenge

August 9, 2010 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Reuters -- Dendreon Corp exaggerated the benefits of its novel prostate cancer vaccine and downplayed risks in some sales materials for the product, U.S. regulators said in a letter released on Friday.

Twitter
LinkedIn
Facebook
Email
Print

Legal Regulatory

Food and Drug Administration (FDA)